Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments

Statistics in Medicine

Volumn 25, Issue 23, 2006, Pages 4004-4019

  Graham, Gordon ^a   Aarons, Leon ^b  

^a Novartis Pharma AG   (Switzerland)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

D optimality; Efficiency; Mixed effects models; Optimum experimental design; Pharmacokinetics; Sampling windows

Indexed keywords

DRUG;

ARTICLE; BIOSTATISTICS; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RESEARCH; EXPERIMENTAL DESIGN; SIMULATION; STATISTICAL MODEL;

BLOOD SPECIMEN COLLECTION; CLINICAL TRIALS, PHASE III; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHLEBOTOMY; TIME FACTORS;

EID: 33947177325     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2512     Document Type: Article

References (29)

1. van Bree J, Nedelman J, Steiner JL, Tse F, Robinson W, Niederberger W. Application of sparse sampling approaches to rodent toxicokinetics: a prospective view. Drug Information Journal 1994; 28:263-279.
2. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977; 5:445-479.
3. Aarons L, Vozeh S, Wenk M, Weiss P, Follath F. Population pharmacokinetics of tobramycin. British Journal of Clinical Pharmacology 1989; 28:305-314.
4. Racine-Poon A, Wakefield J. Statistical methods for population pharmacokinetic modelling. Statistical Methods in Medical Research 1998; 7:63-84.
5. Mandema JP, Verotta, D, Sheiner LB. Building population pharmacokinetic: models. I. Models for covariate effects. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20:511-528.
6. Wakefield J, Bennett J. The Bayesian modelling of covariates for population pharmacokinetic models. Journal of the American Statistical Association 1996; 91:917-926.
7. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of clinical trials. Annual Review of Pharmacology and Toxicology 2000; 40:209-234.
8. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. European Journal of Drug Metabolism and Pharmacokinetics 2000; 25(1):49-58.
9. Gomeni R, Bani M, D'Angeli C, Corsi M, Bye A. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. European Journal of Pharmaceutical Sciences 2001; 13:261-270.
10. Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P. Modelling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan. Pharmaceutical Research 2001; 18:1210-1219.
11. D'Argenio D. Optimal sampling times for pharmacokinetic experiments. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9:739-756.
12. Chernoff H. Locally optimal designs for estimating parameters. Annals of Mathematical Statistics 1953; 24:586.
13. Kiefer J. Optimum experimental designs (with discussion). Journal of the Royal Statistical Society Series B 1959; 21:272-319.
14. Fedorov VV. Theory of Optimum Experiments. Academic Press: New York, 1972.
15. Atkinson AC, Donev AN. Optimum Experimental Designs. Clarenden Press: Oxford, 1992.
16. D'Argenio. Incorporating prior uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Mathematical Biosciences 1990; 33:105-118.
17. Mentré F, Burton P, Merlé Y, van Bree J, Mallet A, Steimer JL. Sparse sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Information Journal 1995; 29:997-1019.
18. Mentré F, Mallet A, Baccar D. Optimal design in random effects regression models. Biometrika 1997; 84: 429-442.
19. Tod M, Rocchisani JM. Comparison of, ED, EID, and API criteria for the robust optimisation of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1997; 25:515-537.
20. Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmaceutical Research 2000; 18:83-89.
21. Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 2002; 21: 2623-2639.
22. Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. European Journal of Clinical Pharmacology 1996; 49:2623-2639.
23. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24:245-263.
24. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics 1991; 19:333-353.
25. Green B, Duffull SB. Prospective evaluation of a D-optimal design population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:145-161.
26. Pronzato L. Information matrices with random regressors. Application to experimental design. Journal of Statistical Planning and Inference 2002; 108:189-200.
27. Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Computer Methods and Programs in Biomedicine 2001; 65:141-151.
28. Matlab User's Guide version 6.1. The MathWorks: Natick, MA, 2001.
29. Boeckman AJ, Sheiner LB, Beal SL. NONMEM users guide. NONMEM Project Group, University of California, San Francisco, 1994.